المؤلفون: Myat, Aung, Arri, Satpal, Bhatt, Deepak L, Gersh, Bernard J, Redwood, Simon R, Marber, Michael S

مصطلحات موضوعية: Glucagon-like peptide-1 receptor agonist, Incretin hormone, Liraglutide, Chronic stable angina, Exercise-induced ischaemia, Type 2 diabetes mellitus

العلاقة: http://www.cardiab.com/content/14/1/27Test

الإتاحة: http://www.cardiab.com/content/14/1/27Test

المصدر: Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06256419Test

المصدر: The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05578352Test

المصدر: FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05526157Test

Other URLs: https://clinicaltrials.bayer.comTest/

المؤلفون: Hangzhou Sciwind Biosciences Co., Ltd.

المصدر: A Phase 1, Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ecnoglutide Tablet in Healthy Adult Participants

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05184322Test

المصدر: Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05037045Test

المؤلفون: Hangzhou Sciwind Biosciences Co., Ltd.

المصدر: A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XW003 Injection in Healthy Adult Participants

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04389775Test

المؤلفون: AstraZeneca

المساهمون: RG IJzerman, Principal Investigator

المصدر: van Bloemendaal L, zerman RG, Ten Kulve JS, Barkhof F, Dmant M, Veltman DJ, van Dukerken E. Alteratns whe matter volume and tegry obesy and type 2 dbetes. Metab Bra D. 2016 Jun;31(3):621-9. do 10.1007/s11011-016-9792-3. Epub 2016 Jan 27.
Ten Kulve JS, Veltman DJ, van Bloemendaal L, Groot PF, Ruhe HG, Barkhof F, Dmant M, zerman RG. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumptn. J Endocrol. 2016 Apr;229(1):1-12. do 10.1530/JOE-15-0461. Epub 2016 Jan 14.
Ten Kulve JS, van Bloemendaal L, Balesar R, zerman RG, Swaab DF, Dmant M, la Fleur SE, Alkemade A. Decreased Hypothalam Glucagon-Le Pepte-1 Receptor Expressn Type 2 Dbetes Patnts. J Cl Endocrol Metab. 2016 May;101(5):2122-9. do 10.1210/jc.2015-3291. Epub 2015 Dec 16.
ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Konrad RJ, Sloan JH, Drent ML, Dmant M, zerman RG. Endogenous GLP-1 medtes postprandl reductns actatn central reward and satty areas patnts wh type 2 dbetes. Dbetolog. 2015 Dec;58(12):2688-98. do 10.1007/s00125-015-3754-x. Epub 2015 Sep 18.
van Bloemendaal L, Veltman DJ, ten Kulve JS, Drent ML, Barkhof F, Dmant M, zerman RG. Emotnal eatg assocted wh creased bra responses to food-cues and reduced sensy to GLP-1 receptor actatn. Obesy (Sver Sprg). 2015 Oct;23(10):2075-82. do 10.1002/oby.21200. Epub 2015 Aug 31.
van Bloemendaal L, Veltman DJ, Ten Kulve JS, Groot PF, Ruhe HG, Barkhof F, Sloan JH, Dmant M, zerman RG. Bra reward-system actatn response to antatn and consumptn of palatable food altered by glucagon-le pepte-1 receptor actatn humans. Dbetes Obes Metab. 2015 Sep;17(9):878-86. do 10.1111/dom.12506. Epub 2015 Jul 22.
van Bloemendaal L, zerman RG, Ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, Veltman DJ, Dmant M. GLP-1 receptor actatn modulates appete- and reward-related bra areas humans. Dbetes. 2014 Dec;63(12):4186-96. do 10.2337/db14-0849. Epub 2014 Jul 28.
van Bloemendaal L, Ten Kulve JS, la Fleur SE, zerman RG, Dmant M. Effects of glucagon-le pepte 1 on appete and body weht: focus on the CNS. J Endocrol. 2014 Mar 7;221(1):T1-16. do 10.1530/JOE-13-0414. Prt 2014 Apr.
Devenny JJ, Godon HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weht loss duced by chron dapaglloz treatment attenuated by compensatory hyperphag dt-duced obese (D) rats. Obesy (Sver Sprg). 2012 Aug;20(8):1645-52. do 10.1038/oby.2012.59. Epub 2012 Mar 8.
FerrannG, Hach T, Crowe S, SanghvA, Hall KD, FerrannE. Energy Balance After Sodm-Glucose Cotransporter 2 hn. Dbetes Care. 2015 Sep;38(9):1730-5. do 10.2337/dc15-0355. Epub 2015 Jul 15.
FerrannE, MuscellE, Frascerra S, BaldS, MarA, Hee T, Broedl UC, Woerle HJ. Metabol response to sodm-glucose cotransporter 2 hn type 2 dbet patnts. J Cl vest. 2014 Feb;124(2):499-508. do 10.1172/JC2227. Epub 2014 Jan 27. Erratum : J Cl vest. 2014 Apr 1;124(4):1868.
Lundkvt P, Perea MJ, Katsognnos P, Sjostrom CD, Johnsson E, Ersson JW. Dapaglloz once day plus exenate once weekly obese adults whout dbetes: Sustaed reductns body weht, glycaem and blood pressure over 1 year. Dbetes Obes Metab. 2017 Sep;19(9):1276-1288. do 10.1111/dom.12954. Epub 2017 May 31.
Frs JP, Guja C, Hardy E, Ahmed A, Dong F, Ohman P, Jabbour SA. Exenate once weekly plus dapaglloz once day versus exenate or dapaglloz alone patnts wh type 2 dbetes adequately controlled wh metform monotherapy (DURATN-8): a 28 week, multentre, double-bld, phase 3, randomed controlled trl. Lancet Dbetes Endocrol. 2016 Dec;4(12):1004-1016. do 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Erratum : Lancet Dbetes Endocrol. 2017 Dec;5(12 ):e8.
Frank S, Laharnar N, Kullmann S, Ve R, Canova C, Hegner YL, Frsche A, Presl H. Processg of food ptures: fluence of hunger, gender and calor content. Bra Res. 2010 Sep 2;1350:159-66. do 10.1016/j.brares.2010.04.030. Epub 2010 Apr 25.
Rothemund Y, Preuschhof C, Bohner G, Bauknecht HC, Klgebl R, Flor H, Klapp BF. Dferentl actatn of the dorsal strtum by hh-calor vual food stul obese duals. Neuroage. 2007 Aug 15;37(2):410-21. do 10.1016/j.neuroage.2007.05.008. Epub 2007 May 18.
Rajeev SP, Cuthbertson DJ, Wdg JP. Energy balance and metabol changes wh sodm-glucose co-transporter 2 hn. Dbetes Obes Metab. 2016 Feb;18(2):125-34. do 10.1111/dom.12578. Epub 2015 Dec 10.
Muskt MH, Tonneck L, Sms MM, Kramer MH, Heerspk HJ, van Raalte DH. Pletrop effects of type 2 dbetes management strategs on renal rk factors. Lancet Dbetes Endocrol. 2015 May;3(5):367-81. do 10.1016/S2213-8587(15)00030-3.
Muskt MHA, Tonneck L, Sms MM, van Baar MJB, Kramer MHH, Hoorn EJ, Joles JA, van Raalte DH. GLP-1 and the kney: from physlogy to pharmacology and outcomes dbetes. Nat Rev Nephrol. 2017 Oct;13(10):605-628. do 10.1038/nrneph.2017.123. Epub 2017 Sep 4.
Murdaugh DL, Cox JE, Cook EW 3rd, Weller RE. fMRreacty to hh-calor food ptures predts short- and long-term outcome a weht-loss program. Neuroage. 2012 Feb 1;59(3):2709-21. do 10.1016/j.neuroage.2011.10.071.
Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03361098Test

المصدر: A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naïve Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02954692Test

المصدر: Herman WH, KalyanRR, Wexler DJ, Matthews DR, zucchSE. Response to Comment on Ameran Dbetes Assoctn. Approaches to Glycem Treatment. Sec. 7. Standards of Medal Care Dbetes-2016. Dbetes Care 2016;39(Suppl. 1):S52-S59. Dbetes Care. 2016 Jun;39(6):e88-9. do 10.2337/dc6-0003. No abstract avaable.
Garber AJ, Abrahamson MJ, Barzay J Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Ehorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hsch , Jellger PS, McGl JB, Mechank J Rosenbl PD, Umprrez GE; Ameran Assoctn of Clal Endocrologts (AACE); Ameran College of Endocrology (ACE). CONSENSUS STATEMENT BY THE AMERAN ASSOCTN OF CLAL ENDOCROLOGTS AND AMERAN COLLEGE OF ENDOCROLOGY ON THE COMPREHENSE TYPE 2 DBETES MANAGEMENT ALGORHM--2016 EXECUTE SUMMARY. Endocr Pract. 2016 Jan;22(1):84-113. do 10.4158/EP151126.CS. No abstract avaable.
Dmant M, Nauck MA, Shagn R, Malone JK, Cleall S, Reaney M, de Vrs D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH; 4B Study Group. Glucagon-le pepte 1 receptor agont or bolus sul wh opted basal sul type 2 dbetes. Dbetes Care. 2014 Oct;37(10):2763-73. do 10.2337/dc14-0876. Epub 2014 Jul 10.
Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02846233Test